1-800-330-9928 Email Sign Up Contact Us MENU Home About Us About Us Board Of Directors W. James O’Shea – Chairman Mark H. Corrigan, M.D. – GNC Chair Richard M. Glickman, L.L.D. (Hon) – LID William Hunter, M.D. – President and CEO Robert James Meyers, M.D. Arthur H. Willms – AC Chair Management William Hunter, M.D. – President and CEO Sheila Grant – COO Jennifer Archibald, CA – CBOO Hugues Sachot – CCO David Dean – Chief BDO David McMasters – General Counsel Justin A. Renz, CPA, MST, MBA – CFO Products Products Commercialized AGGRASTAT ® BRINAVESS ® ESMOCARD ® AND ESMOCARD LYO ® EXEMBOL ® XYDALBA ™ In Development TREVYENT ® Therapeutic Areas Acute Bacterial Skin and Skin Structure Infections Acute Coronary Syndromes Atrial Fibrillation Heparin Induced Thrombocytopenia Type II Pulmonary Arterial Hypertension Supraventricular Tachycardia Report an Adverse Event or a Product Quality Complaint Medical Information Partners Partners Out-licensing In-licensing Contact Business Development Investors & Media Investors Financial Reports and Regulatory Filings Press Releases Corporate Presentation Corporate Governance Investor FAQs Contact IR Careers Careers Current Opportunities How to apply About your application Innovation for Patients Cardiome’s mission is to offer patients and healthcare providers innovative therapeutic options that effectively, safely, and conveniently manage acute medical conditions to improve health and quality of life Discover More Products Improving patient health, one treatment at a time Discover More News Cardiome Announces Commercial Launch of XYDALBA™ (dalbavancin) in Germany Discover More Investors Cardiome Reports Third Quarter 2016 Financial Results Discover More Recent News View More >> September 12, 2017 Cardiome Announces Agreement with Basilea for Distribution of ZEVTERA®/MABELIO® (CEFTOBIPROLE) in Europe and Israel September 5, 2017 Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference August 30, 2017 New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS® August 21, 2017 Cardiome Provides U.S. Regulatory Update for BRINAVESS August 8, 2017 Cardiome Reports Second Quarter 2017 Financial Results August 1, 2017 Cardiome to Hold Second Quarter 2017 Financial Results Conference Call on August 8 July 17, 2017 Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen June 23, 2017 Cardiome Announces Voting Results June 21, 2017 Cardiome Announces Licensing Agreement for XYDALBA™ (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel July 3, 2017 Cardiome’s Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension Products View More >> View Products STOCK INFORMATION View More >> NASDAQ (CRME) TSX (COM) CRME $2.34 0.03 (0.85%) Open: Day High: 52 Week High: 2.31 2.35 4.84 Previous Close: Day Low: 52 Week Low: 2.36 2.29 2.09 Volume: 108461 View External NASDAQ Listing View External TSX Listing *Timestamp may be delayed due to API limitations Terms of Use Privacy Statement Transparency Sitemap Copyright 2015 Cardiome Pharma Corp. All rights reserved. By following this link you will be leaving the Cardiome.com website. Please note that Cardiome does not take responsibility for the content displayed on other websites: ContinueClose